Summary
There is now widespread interest in the subject of drug dose intensity in cancer treatment. Recent retrospective analyses have shown a clear-cut benefit for those patients receiving either the intended drug dosage in a particular regimen or the highest dosage achievable through an escalation scheme. In this discussion, the participating physicians will review dose intensity in light of these retrospective studies, highlighting the particular tumor types in which benefits have been demonstrated. Other important issues will be discussed, such as scheduling of drug combinations and the importance of using toxicity as a biologic response monitor of drug efficacy. The panelists will also provide opinions as to the best design for aprospective clinical trial to test dose intensity.
This is a preview of subscription content, log in via an institution to check access.
Author information
Authors and Affiliations
Additional information
A series of teleconferences has been organized under the auspices of Bristol-Myers to address several major current questions in oncology. A panel of recognized experts with a moderator has been assembled to discuss each question, and we are reporting a number of these discussions in Breast Cancer Research and Treatment. This is reprinted from ‘Oncology Viewpoints’, courtesy of Bristol-Myers Oncology Division, Evansville IN 47721, USA.
Rights and permissions
About this article
Cite this article
McGuire, W.L., Goldie, J., Hryniuk, W. et al. Drug dosage intensity — a panel discussion. Breast Cancer Res Tr 9, 87–100 (1987). https://doi.org/10.1007/BF01807361
Issue Date:
DOI: https://doi.org/10.1007/BF01807361